Price T Rowe Associates Inc Kymera Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,859,202 shares of KYMR stock, worth $273 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,859,202
Previous 6,702,450
2.34%
Holding current value
$273 Million
Previous $183 Million
63.17%
% of portfolio
0.03%
Previous 0.02%
Shares
19 transactions
Others Institutions Holding KYMR
# of Institutions
191Shares Held
69.7MCall Options Held
223KPut Options Held
241K-
Avoro Capital Advisors LLC New York, NY6.56MShares$261 Million5.22% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$239 Million1.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$224 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA5.37MShares$214 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$206 Million6.21% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.18B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...